A Randomized, Controlled, Open-Label, Multicenter, Phase 2 Study of Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine as First-Line Treatment in Patients With Recurrent/Metastatic Triple Negative Breast Cancer
试验速览
- 阶段
- 2 期
- 入组人数
- 90
- 试验地点
- 9
- 主要终点
- ORR
研究概览
简要总结
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR), inhibiting tyrosine kinase activation. This is a randomized, controlled, open-Label, multicenter, phase Ⅱ clinical trial of nimotuzumab plus Docetaxel and Capecitabine（TX）versus Docetaxel and Capecitabine（TX）as first-line treatment in patients with recurrent/metastatic triple negative breast cancer.
详细描述
The control group received docetaxel + capecitabine regimen;Experimental group received Nimotuzumab combined docetaxel + capecitabine regimen.The main purpose is to evaluate Nimotuzumab Plus Docetaxel and Capecitabine（TX）as First-Line Treatment in Patients With Recurrent/Metastatic triple negative breast cancer would improve objective response rate (ORR ) comparing with Docetaxel and Capecitabine（TX）.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histological and immunohistochemistry (IHC) confirmed recurrent or metastatic triple-negative breast cancer .
- •Previous chemotherapy should include anthracycline or taxane; No prior chemotherapy after metastasis.
- •Females with age between 18 and 70 years old
- •ECOG performance status 0 or
- •At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST) by magnetic resonance imaging, or computed tomography; The target lesions is Unresectable; The target lesions did not receive radiotherapy or relapse within the radiation field;
- •Life expectancy ≥ 12 weeks.；
- •WBC count ≥ 4 × 109 / L, neutrophils ≥ 1.5 × 109 / L, platelet count ≥ 100 × 109 / L, hemoglobin ≥ 6.21mmol / L (10 g / dL);
- •Total bilirubin (TBL)≤ 1.5 x ULN (upper limit of normal reference values); AST and ALT ≤ 2.5 x ULN or ≤ 5 ULN (Liver metastasis);Serum creatinine ≤ 1.5 x ULN.
- •Before enrollment, patients have fully recovered from previous treatment-related toxicity;
- •Subjects with fertility must accept effective contraceptive measures;
- •Signed informed consent
排除标准
- •Previously treatment regimen including anti EGFR monoclonal antibody;
- •Receiving other anti-cancer medicine treatment during the study
- •Participate in other clinical trials within 4 weeks in this group;
- •Accepted taxane treatment in 1 year;
- •Presence of neurological symptoms due to brain metastasis, patients receiving steroidal anti-edema drugs therapy;
- •Patients having a history of clinically significant symptomatic angina, arrhythmia or congestive heart failure without control;
- •Diagnosed with severe interstitial pneumonitis or pulmonary fibrosis by chest CT;
- •Pleural effusion, ascites require to be drained;
- •Adverse drug addiction and drug abuse, long-term alcoholics, as well as AIDS patients; patients with severe or uncontrolled complications, such as infection requiring systemic therapy, fever (≥ 38 ℃), diabetes or hypertension can not be controlled by medicine, other complications may interfere with drug therapy;
- •Patients with a history of drug allergy (≥ CTCAE 2 level) such as shock or allergic symptoms, especially have allergic reactions to similar drugs in the past, have severe allergies reactions to drugs containing polysorbate eighty (Tween 80);
- •Uncontrolled seizures or loss of insight due to mental disorders;
- •Pregnant or lactating women；
- •Researchers think improper for this trial
研究组 & 干预措施
Nimotuzumab,docetaxel,capecitabine
Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
干预措施: Nimotuzumab (Drug)
Nimotuzumab,docetaxel,capecitabine
Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
干预措施: docetaxel (Drug)
Nimotuzumab,docetaxel,capecitabine
Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
干预措施: capecitabine (Drug)
docetaxel,capecitabine
Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
干预措施: docetaxel (Drug)
docetaxel,capecitabine
Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
干预措施: capecitabine (Drug)
结局指标
主要结局
ORR
时间窗: every six weeks, up to 1 year
Evaluation ORR every six weeks,with RECIST 1.1.
次要结局
- Number and ratio of AEs(up to 1 year)
- PFS(every six weeks, up to 1 year)
- Relationship of tissue/serum EGFR between efficacy and prognosis(1 year)
研究者
Binghe Xu
Director of Medical Oncology
Chinese Academy of Medical Sciences